P15 methylation before and after decitabine therapy
. | All patients, N = 29 . | CR + PR, n = 7 . | NR, n = 18 . | Inevaluable, n = 4 . |
|---|---|---|---|---|
| Before Rx | ||||
| Mean, % | 11.2 | 5.2 | 13.9 | 9 |
| Median, % | 10.6 | 0 | 13 | 5.5 |
| More than 10%, n (%) | 15 (52) | 2 (29) | 11 (56) | 2 (50) |
| After Rx* | ||||
| Mean, % | 11.5 | 6.7 | 14.3 | 6.2 |
| Median, % | 3 | 1.5 | 10.3 | 0 |
| More than 10%, n (%) | 11/25 (44) | 2/6 (33) | 8/16 (50) | 1/3 (33) |
. | All patients, N = 29 . | CR + PR, n = 7 . | NR, n = 18 . | Inevaluable, n = 4 . |
|---|---|---|---|---|
| Before Rx | ||||
| Mean, % | 11.2 | 5.2 | 13.9 | 9 |
| Median, % | 10.6 | 0 | 13 | 5.5 |
| More than 10%, n (%) | 15 (52) | 2 (29) | 11 (56) | 2 (50) |
| After Rx* | ||||
| Mean, % | 11.5 | 6.7 | 14.3 | 6.2 |
| Median, % | 3 | 1.5 | 10.3 | 0 |
| More than 10%, n (%) | 11/25 (44) | 2/6 (33) | 8/16 (50) | 1/3 (33) |
CR + PR indicates complete and partial remissions; NR, no response; inevaluable, inevaluable for a response; and Rx, decitabine therapy.
Excludes 4 patients for whom post-Rx samples were not available.